Anetumab ravtansine is under clinical development by Bayer and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase I drugs for Gastroesophageal (GE) Junction Carcinomas have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Anetumab ravtansine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Anetumab ravtansine overview
Anetumab ravtansine (BAY 94-9343) is under development for the treatment of advanced solid tumors including epithelial ovarian cancer, primary peritoneal cancer, fallopian tube cancer, advanced metastatic pancreatic cancer, endometrial cancer, serous uterine cancer. It is also under development in combination with pegylated liposomal doxorubicin for the treatment of platinum-resistant ovarian cancer, fallopian tube cancer and peritoneal cancer. The drug candidate is administered as an intravenous infusion. It is a fully human HuCAL-derived antibody. The antibody-drug conjugate mesothelin-ADC is being developed to target the antigen mesothelin. BAY 94-9343 is based on the targeted antibody payload (TAP) technology and HuCAL GOLD Technology.
It was also under development for the treatment of lung adenocarcinoma, malignant pleural mesothelioma, nonsquamous non-small cell lung cancer (NSCLC), triple-negative adenocarcinoma of the breast, pancreatic cancer, gastric cancer (including the gastro-esophageal junction), colon cancer, cholangiocarcinoma and thymic carcinoma
Bayer is engaged in the discovery, development, manufacturing, and commercialization of products for human health, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology, and other indications. It also strives to develop new molecules and technologies for use in the fields of medicine and modern agriculture. The company’s product portfolio includes prescription products, specialty pharmaceuticals, diagnostic imaging equipment, non-prescription (over the counter or OTC) products, seeds, crop protection solutions and non-agricultural pest control solutions. Bayer markets its healthcare and crop protection products essentially through wholesalers, pharmacies, hospitals, and retailers. It operates through a network of subsidiaries in Asia-Pacific, Europe, North America, Latin America, Africa, and the Middle East. Bayer is headquartered in Leverkusen, North Rhine-Westphalia, Germany.
For a complete picture of Anetumab ravtansine’s drug-specific PTSR and LoA scores, buy the report here.